Heal Capital’s Post

🚀 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗲𝗰𝘂𝗿𝗲𝘀 €𝟲.𝟮𝗠 𝗶𝗻 𝗦𝗲𝗲𝗱 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗼 𝗘𝗻𝗵𝗮𝗻𝗰𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗔𝗜-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗣𝗿𝗼𝗴𝗻𝗼𝘀𝗶𝘀 𝗧𝗲𝘀𝘁𝘀 🚀 Big news! 🌟 Spotlight Medical has raised €6.2 million in a seed funding round led by Kurma Partners and Heal Capital. This funding will bring our first AI-driven prognosis test to the clinic, towards significantly improving cancer treatment strategies. 👉 𝗪𝗵𝗮𝘁 𝗧𝗵𝗶𝘀 𝗠𝗲𝗮𝗻𝘀: By leveraging decades of patient data, our AI technology ensures personalized, effective cancer care, improving outcomes for all patients. This funding is a major milestone in our mission to harness AI for better cancer treatment decisions. 🗣 𝗩𝗼𝗶𝗰𝗲𝘀 𝗳𝗿𝗼𝗺 𝗢𝘂𝗿 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀: Benjamin Belot, partner at Kurma Partners: “We were impressed by the quality of the team and their unique technology, unlike anything in precision oncology.” Christian Lautner, partner at Heal Capital: “We are convinced the Spotlight Medical team is perfectly positioned to bring an AI-empowered precision oncology platform to clinical practice and thereby have a lasting impact on patients’ lives.” Sylvain Berlemont, CEO of Spotlight Medical, said, “We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment.” 🔬 𝗔𝗯𝗼𝘂𝘁 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗠𝗲𝗱𝗶𝗰𝗮𝗹: Founded in 2024 and backed by renowned cancer centers Institut Curie and Gustave Roussy, we develop advanced AI tests to enhance treatment selection. Our goal? To ensure no patient is over or undertreated. Check the comments for the full press release link! #TechForGood #CancerResearch #AI #PrecisionMedicine #Innovation #Healthcare #Oncology #Seedfunding

🚀 Revolutionizing Cancer Care: A New Era in Oncology 🚀 The landscape of cancer treatment is undergoing a revolutionary transformation, driven by groundbreaking innovations. These developments are reshaping our approach to care and improving patient outcomes. 💡 Key advancements in oncology include: ✨ Immunotherapy: Harnessing the body’s immune system to precisely target cancer cells. CAR-T cell therapies and checkpoint inhibitors are showing significant promise in treating previously difficult-to-treat cancers. 🔬 Liquid Biopsies: A non-invasive method to detect and monitor cancer through blood tests, enabling earlier detection and more timely interventions. 🧬 Precision Medicine: Personalizing treatment plans based on genetic profiles, ensuring more effective therapies with fewer side effects for patients. 🤖 AI & Big Data: Leveraging artificial intelligence and data analytics to accelerate research, predict treatment responses, and create individualized cancer care strategies. Join us at the Cancer Care Conference - Global Edition to delve into these revolutionary developments and explore how they are shaping the future of cancer care. 🎯 Let’s collaborate and push the boundaries of oncology research and treatment. . . . #RevolutionizingCancerCare #CancerResearch #OncologyInnovation #Immunotherapy #LiquidBiopsy #PrecisionMedicine #AIinHealthcare #CancerCareAdvancement #CancerTreatment #CancerCareRevolution #OncologyResearch #MedicalInnovation #TargetedTherapy #PrecisionOncology #CancerAwareness #CancerFighting #HealthTech #MedicalBreakthroughs #OncologyCare #CancerPrevention #NextGenCancerCare #HealthcareInnovation #CancerTherapies #OncologyCommunity

🔍 Sybil - Promising Breakthrough in Lung Cancer Screening! “We found that while we [as humans] couldn’t quite see where the cancer was, the model could still have some predictive power as to which lung would eventually develop cancer." - Jeremy Wohlwend For lung patients and those at risk of lung cancer, a tool called Sybil could revolutionize the way we approach lung cancer screening. 😮 This deep learning model could predict lung cancer risk up to SIX years in advance from a single low-dose CT scan (LDCT) – and the best part? It doesn’t require any additional clinical data or annotations from radiologists. Developed using CT data from the National Lung Screening Trial (NLST), Mass General Hospital (MGH), and CGMH, Sybil has been validated across diverse patient groups, achieving impressive accuracy: "...models achieving a C-index score over 0.7 are considered good and over 0.8 is considered strong. The ROC-AUCs for one-year prediction using Sybil scored even higher, ranging from 0.86 to 0.94, with 1.00 being the highest score possible." 🤔 Generalized across U.S. and international data, including nonsmokers. This technology could drastically improve personalized screening, helping identify patients who need closer monitoring or fewer follow-up scans, improving outcomes while reducing unnecessary procedures. *Additional research is required to understand Sybil's clinical applications. 📣 As we wait for updates, countless people impacted by lung cancer and I are cheering on the many brilliant team members working on Sybil. 🙏 Thank you for your time and dedication. Here are a few of the team members who had contributed or are contributing to Sybil: Regina Barzilay Florian J. Fintelmann MD Ignacio Fuentes Ribas Stefan Ringer Ludvig Karstens Justin Xiang Jeremy Wohlwend #PatientCentricOncologyClinicalTrials #Sybil #LungCancer #ArtificialIntelligence #CTScan #HealthTech #EarlyDetection #DeepLearning #MachineLearning #MIT #NLST #MGH #CGMH #LungCancerScreening #OncologyClinicalTrials #CancerClinicalTrials

🚀 𝐄𝐋𝐌𝐔𝐌𝐘 𝐉𝐨𝐢𝐧𝐭 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐄𝐔-𝐅𝐮𝐧𝐝𝐞𝐝 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐬: 𝐌𝐔𝐋𝐓𝐈𝐑 𝐚𝐧𝐝 𝐒𝐓𝐄𝐏𝐔𝐏𝐈𝐎𝐑𝐒! 🚀 On October 3rd, 2024, we at 𝐄𝐋𝐌𝐔𝐌𝐘 were thrilled to join forces with the EU-funded projects MULTIR EU Project and STEPUPIORS Horizon Europe Twinning Project for an engaging joint session aimed at advancing cancer research. This event was an incredible opportunity to present our latest research and achievements while exploring synergies with these outstanding initiatives. ✨ 𝐌𝐔𝐋𝐓𝐈𝐑 is focused on predicting and manipulating immune responses in multiple cancer types, including melanoma, lung, and bladder cancers.   🔍 𝐒𝐓𝐄𝐏𝐔𝐏𝐈𝐎𝐑𝐒 is working to define prognostic biomarkers in rectal cancer, contributing vital insights to cancer research. 📊 𝐄𝐋𝐌𝐔𝐌𝐘 continues to focus on identifying risk factors and health determinants that lead to the progression of monoclonal gammopathies into multiple myeloma. As part of the #𝐌𝐢𝐬𝐬𝐢𝐨𝐧𝐂𝐚𝐧𝐜𝐞𝐫 initiative and 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐂𝐥𝐮𝐬𝐭𝐞𝐫, we’ve found great opportunities for collaboration with related projects. 𝑺𝒆𝒔𝒔𝒊𝒐𝒏 𝑯𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒔: - 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧𝐬 from all three projects, showcasing innovative research and solutions.   - Dynamic 𝐐&𝐀 𝐬𝐞𝐬𝐬𝐢𝐨𝐧𝐬, where attendees explored the impact and future goals of each project.  We are grateful for the opportunity to collaborate with these exceptional teams and look forward to continuing to push the boundaries of cancer research and innovation together! 🚀 #ELMUMY #MULTIR #STEPUPIORS #CancerResearch #Collaboration #Synergy #MissionCancer #UnderstandingCluster #InnovativeScience

🚀 Empowering Breast Cancer Patients with AI: A Game-Changer in Healthcare! 🚀 We're thrilled to announce a groundbreaking collaboration between the Samueli Institute at #DavidoffCenter, Beilinson - Rabin Medical Center, and the innovative startup XOLTAR. Together, we're launching Project #EngageX, an AI-powered Avatar designed to revolutionize care for #BreastCancer patients. EngageX aims to monitor and manage the notorious side effects using natural conversation, and thereby improve quality of life and potentially survival outcomes.🌸 💡 Why EngageX is a Game-Changer: ➡ 24/7 AI-powered side effect management ➡ Personalized, natural free conversation ➡ Alert system for medical team intervention ➡ Data collection for treatment optimization This innovative application, developed by XOLTAR, is backed by the Davidoff Center's Breast Cancer Unit and Samueli Integrative Cancer Pioneering Institute, in partnership with Novartis Israel. Click on the video, meet Xara, and join us in making a difference in breast cancer care! 🌟 Avner Paz-Tsuk Asaf Shiloni Rinat Yerushalmi Sivan Agranat Elad Maron Maya Balan #HealthcareInnovation #AIinHealthcare #PatientCare #CancerResearch #HealthTech #WomenInTech #AIForGood #Oncology

Thanks Nias for representing Azra AI at the Lung Cancer Innovation Day and showcasing how our cutting-edge AI solutions are transforming oncology care. Events like this highlight the incredible strides being made in personalizing and improving cancer treatment through collaboration and innovation.   And thank you to AstraZeneca and Plug and Play Tech Center for bringing together such a dynamic community of leaders, visionaries, and change-makers in oncology. The discussions on AI’s transformative role and biomarker-driven treatments reaffirm our commitment to pushing the boundaries of possibility in lung cancer care.   At Azra AI, we’re passionate about delivering solutions that empower healthcare teams, enhance workflows, and ultimately ensure no patient falls through the cracks. Here's to advancing smarter, more personalized, and patient-centered care—together.

[OncoThursdays] Exciting advancement in oncology by utilizing machine learning (ML) models to predict pathologic complete response (pCR). Researchers have used data from over 2,000 patients to create a model that analyzes specific patient details, like tumor characteristics and treatment history, to predict whether the cancer will completely disappear (pathologic complete response or pCR) after NAC. The best-performing ML model (LightGBM) was highly accurate, especially for certain breast cancer subtypes. What’s exciting is how this technology helps doctors make more personalized treatment plans. Instead of a one-size-fits-all approach, ML models can predict which patients are most likely to benefit from specific treatments. This means fewer unnecessary side effects and better outcomes for patients. Studies show how advanced technologies like machine learning are changing cancer care by improving predictions, saving time, and offering more tailored treatments for each patient. It’s a step toward making cancer treatments smarter and more effective. 🔔Let’s explore the latest insights and advancements together. Follow me in my journey of [OncoThursdays], where I'll be sharing insights and innovations in cancer care. Every Thursday, I'll spotlight breakthroughs and tools advancing oncology, from Al applications, case reports, to personalized treatments. #oncology #innovation

New year, new beginnings! Over the past few months, Roald Kruit & Carli Wischhoff established Yamicc foundation. Yamicc, which stands for ‘You And Me In Curing Cancer’, is on a mission to find effective treatments for patients with rare cancer, aiming for the highest quality of life. Although groundbreaking progress has been made in cancer research over the past years, there are still fundamental challenges that hinder progress in curing these patients. A small group of passionate entrepreneurs with extensive expertise in leveraging innovative technologies such as artificial intelligence have joined forces with a group of experienced and specialized medical experts to make a difference. Instrumental in our approach is the collection of comprehensive datasets of these rare cancers in a standardized and structured manner. Data is initially collected via clinical trials that are conducted in the UMCs. To facilitate and support the collection of the necessary data, Yamicc will orchestrate a data-driven research platform that facilitates easily and securely collecting, processing, and sharing data in a governed way. As such, coordinating large-scale collaboration with international medical institutions, researchers, and (bio)technologists is essential to all our endeavors. At heart, we like to think big, act small and automate to the fullest extent to ultimately cure cancer together. With those core values, we strive to trigger a paradigm shift in rare cancer treatments. Are you joining too? Follow this page for news, updates and future content on our work. For more details, take a look on our website (www.yamicc.org) or reach out in case you would like to connect live. Yamicc wouldn’t be here without the efforts of some bold people from different corners of our (oncology) community, thanks to you and looking forward to collaborate with many more! Clemens Dirven Bert van der Schelde Henk Verheul Marjolein Geurts Martine Lamfers Stijn Koolen Judith Verhagen-Oldenampsen Puspha Achaiber Sing Tim Kuijper Sascha Oosterbaan Manon Quaak Mark Wegman Alexander (Lex) Eggermont MD, PhD Erik Heddema Charlotte Verkeyn and more!

𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 🖲 Invenio Imaging's latest milestone is a game-changer in the world of diagnostic imaging. Congratulations to Jonathan Ross and the team, as this is a testament to their hard work! The completion of enrolment in the pivotal ON-SITE trial marks a significant step forward in the fight against lung cancer. Partnering with Johnson & Johnson, this multi-centre trial aims to validate the NIO Laser Imaging System, a groundbreaking AI-driven solution designed to fill the critical gaps in lung biopsy procedures. Lung cancer diagnosis has long been constrained by the availability of rapid-on-site tissue evaluation (ROSE), requiring specialized personnel that many centres lack. With the NIO system, Invenio offers a promising alternative—an AI-based image analysis module that provides the precision of ROSE without the need for a cytologist on-site. This innovation not only speeds up the process but also ensures that even centres with limited resources can deliver high-quality care. This is more than just a technological advance; it's a potential life-saver, offering faster, more accurate, and more accessible lung cancer diagnosis. The ON-SITE trial could pave the way for FDA clearance, bringing us one step closer to transforming how we detect and treat one of the deadliest forms of cancer. 🔗 #LungCancer #AI #MedicalDevices #Innovation #J&J #InvenioImaging #ClinicalTrials

#MTWEcosystem 🌍 As AI continues to advance in healthcare, Check4Cancer is dedicated to a patient-first approach. Their mission? To create accessible and accurate cancer detection methods that bring cutting-edge care to those who need it most. As they focus on AI-driven models for skin cancer detection, Check4Cancer recognizes the power of collaboration. They’re on the lookout for partnerships with startups and MedTech innovators who share their vision for improving patient outcomes. 🤝 Curious about how Check4Cancer is changing the landscape of cancer detection? Read more! https://lnkd.in/d-XQ9NDR